Bio-Rad tallied net sales of $551.5 million compared to $500.1 million in Q1 2017, driven by growth in both its Life Science and Clinical Diagnostics businesses.
The assay could provide detection of HBV infection at early stages, potentially preventing progression to cirrhosis or hepatocellular carcinoma.
Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.
In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.
The firm has provided glimpses into its strategies for developing a line of regulated droplet digital PCR tests in a number of recent forums.
Researchers identified somatic KRAS mutations in affected tissue from more than 60 percent of people with sporadic arteriovenous malformations of the brain.
The test uses droplet digital PCR to detect BCR-ABL gene fusions and is intended for treatment response monitoring of chronic myeloid leukemia.
The team has developed a method to test for inherited disorders prenatally and plan to conduct a larger trial and eventually offer it as a clinical test.
Third quarter sales of $535.0 million beat analysts' average estimate of $508 million and represented 3 percent growth on a currency-neutral basis.
The firm has not published validation studies for the test, but new data last week has provided more support for the methylation-based method at its heart.
Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.
The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.
Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.
In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.